^
    10d
    TYR300-203: A study to investigate dabogratinib (TYRA-300) in participants with Low Grade Upper Tract Urothelial Carcinoma (2025-523539-20-00)
    P1/2, N=12, Not yet recruiting, Tyra Biosciences Inc.
    New P1/2 trial
    |
    dabogratinib (TYRA-300)
    14d
    TYR300-101: A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors (2023-507589-22-00)
    P1/2, N=75, Completed, Tyra Biosciences Inc. | Suspended --> Completed
    Trial completion
    |
    FGFR3 mutation
    |
    dabogratinib (TYRA-300)
    26d
    A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=190, Completed, Hutchison Medipharma Limited | Recruiting --> Completed | N=141 --> 190 | Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Sep 2024 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • fanregratinib (HMPL-453)
    28d
    111-303: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children With Hypochondroplasia (2024-513129-22-00)
    P2/3, N=22, Completed, Biomarin Pharmaceutical Inc. | Recruiting --> Completed
    Trial completion
    1m
    A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment (clinicaltrials.gov)
    P2, N=30, Recruiting, BioMarin Pharmaceutical | N=54 --> 30
    Enrollment change
    1m
    333-301: A study of BMN 333 versus Vosoritide in Children with Achondroplasia (2025-523811-12-00)
    P2/3, N=25, Not yet recruiting, Biomarin Pharmaceutical Inc.
    New P2/3 trial
    2ms
    J4G-MC-JZVD: A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) (2025-522855-25-00)
    P2/3, N=197, Not yet recruiting, Eli Lilly & Co.
    New P2/3 trial
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • vepugratinib (LY3866288)
    2ms
    ASPEN: Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia (clinicaltrials.gov)
    P2/3, N=160, Recruiting, BioMarin Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=110, Active, not recruiting, Cogent Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    CGT4859
    3ms
    A Monotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    segigratinib (3D185)
    3ms
    Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, University of California, San Francisco | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    3ms
    Design, synthesis, and Lead optimization of novel Quinazoline-based FLT3 inhibitors with potent anti-acute myelogenous leukemia activity. (PubMed, Bioorg Med Chem Lett)
    Guided by a scaffold-hopping strategy based on G-749 (denfivontinib), a series of quinazoline-based derivatives was designed and synthesized to explore structure-activity relationships (SAR)...Mechanism studies indicated that W4 induced G0/G1 cell cycle arrest and apoptosis, accompanied by a reduction in intracellular reactive oxygen species levels and a loss of mitochondrial membrane potential. Collectively, these results identified W4 as a potent FLT3 inhibitor and provided valuable SAR insights for further scaffold optimization.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    FLT3 mutation
    |
    denfivontinib (SKI-G-801)